Patent ID: 7713696
Filing Date: 2010-05-11
Classification: C12Q

Abstract:
1. A method for predicting clinical responsiveness to methotrexate therapy in a human afflicted with, or at risk of developing, rheumatoid arthritis comprising: detecting the presence of a 34C>T polymorphism in the adenosine monophosphate deaminase (AMPD1) gene, and determining the patient's genotype at position 347 of the aminoimidazole carboxamide ribonucleotide transformylase (ATIC) gene and at position 94 of the inosine triphosphate pyrophosphatase (ITPA) gene, wherein the presence of said polymorphism, a CC genotype at position 347 of the ATIC gene, and a CC genotype at position 94 of the ITPA gene is indicative of clinical responsiveness to said methotrexate therapy.